Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MNPR
HOLDMonopar Therapeutics Inc. · Healthcare · United States · $736M · Avg Vol: $24M/d
COMPANY DESCRIPTION
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe cancers. Its proprietary drug candidates target mechanisms that address chemotherapy-induced toxicities and resistance, alongside novel anti-cancer agents. Monopar operates as a niche player in oncology, aiming to improve outcomes for patients with difficult-to-treat cancers and significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 15.8M | — |
| EPS | -3.65 | -1.60 | -1.35 | -4.11 | -1.85 | — | -1.83 | -2.90 | -3.13 | — |
| Shares | 2.5M | 6.7M | 6.7M | 6.1M | 6.7M | +165.6% | 6.7M | — | — | — |
| Debt | 0 | 8.4K | 0 | 0 | 0.2M | 164.1% | 0.2M | — | — | — |
| Equity | 18.9M | 10.1M | 5.6M | 55.0M | 137.8M | 64.2% | — | — | — | — |
| Op CF | -7.3M | -7.2M | -7.9M | -6.4M | -12.2M | — | -10.0M | — | — | — |
| Inv CF | 0 | -4.9M | 4.9M | -14.3M | -63.5M | — | — | — | — | — |
| Fin CF | 10.9M | 32.9K | 2.0M | 59.3M | 91.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MNPR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MNPR | Monopar Therapeutics Inc.(you) | $736M | 44 | HOLD |
| FTH | Faeth Therapeutics, Inc. | $729M | 49 | HOLD |
| CLYM | Climb Bio, Inc. | $735M | 39 | HOLD |
| 0KCS.L | OPKO Health, Inc. | $734M | 37 | HOLD |
| LBRX | LB Pharmaceuticals Inc | $1.0B | 42 | HOLD |
| GYRE | Gyre Therapeutics, Inc. | $662M | 37 | HOLD |
| CADL | Candel Therapeutics, Inc. | $700M | 35 | SELL |
| OMER | Omeros Corporation | $709M | 33 | SELL |
| NGNE | Neurogene Inc. | $696M | 33 | SELL |
| RLMD | Relmada Therapeutics, Inc. | $544M | 51 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%